Clinical reference Biomarker Directory
Back to directory

Pyruvate Kinase

Established

Pyruvate kinase deficiency causes chronic hemolytic anemia, now treatable with a novel oral enzyme activator (mitapivat).

Also known as PK deficiency PKLR enzyme
In plain language

This enzyme helps red blood cells make energy. Without enough of it, cells break down too easily, causing lifelong anemia. A new pill medication was recently approved that directly boosts this enzyme's activity — the first real treatment beyond blood transfusions and spleen removal for this condition.

Biomarker & context

Pyruvate kinase is a key enzyme in red blood cell glycolysis (energy metabolism); its deficiency is a rare inherited cause of chronic hemolytic anemia due to impaired red cell energy production.

What it indicates

Low pyruvate kinase enzyme activity confirms pyruvate kinase deficiency in a patient with chronic non-spherocytic hemolytic anemia, jaundice, and splenomegaly, typically presenting from infancy through adulthood with variable severity.

Diagnosis & clinical testing

Measured via red blood cell enzyme activity assay; genetic testing of the PKLR gene can confirm diagnosis and inform genetic counseling, since the condition is autosomal recessive.

Guiding treatment

A specific pyruvate kinase activator drug (mitapivat) was approved in recent years, giving this previously untreatable enzyme deficiency an actual disease-modifying oral therapy for the first time, rather than relying solely on supportive care (transfusions, splenectomy) as in the past.

Clinical significance

Represents a rare case of a previously untreatable enzyme deficiency gaining a genuine disease-modifying drug.

References
  1. General hematology reference literature on pyruvate kinase deficiency and mitapivat as a novel enzyme activator therapy.